Advanced cholangiocarcinoma therapy: enhanced drug delivery via targeted nanocarriers

• Targeted nanocarriers significantly enhance drug delivery to cholangiocarcinoma cells, improving therapeutic efficacy. • The system reduces systemic toxicity compared to conventional chemotherapy, offering a safer treatment option. • In vivo studies demonstrate substantial tumor growth inhibition in mouse models, validating the approach. • The nanocarrier platform can be adapted for other cancers by modifying the targeting ligand, broadening its clinical impact.